metoprolol has been researched along with Cirrhosis in 19 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " The purpose of this study was to verify whether metoprolol regulates AKAP5 expression and test the role of AKAP5 postinjury in mitigating cardiac infarction-associated tissue remodeling and fibrosis." | 8.12 | Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart. ( Wang, H; Wang, Q; Wang, Z; Zhang, B; Zhang, X; Zhu, F, 2022) |
| "Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA." | 7.81 | Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 7.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 7.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " The purpose of this study was to verify whether metoprolol regulates AKAP5 expression and test the role of AKAP5 postinjury in mitigating cardiac infarction-associated tissue remodeling and fibrosis." | 4.12 | Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart. ( Wang, H; Wang, Q; Wang, Z; Zhang, B; Zhang, X; Zhu, F, 2022) |
| "Background Whether chronic obstructive sleep apnea ( OSA ) could promote epicardial adipose tissue ( EAT ) secretion of profibrotic adipokines, and thereby contribute to atrial fibrosis, and the potential therapeutic effects of metoprolol remain unknown." | 3.91 | Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea. ( Dai, H; Gong, Y; Han, Y; Li, T; Li, Y; Sheng, L; Sun, L; Xu, J; Yin, S; Yuan, Y; Zhang, Y, 2019) |
| "Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
| "Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA." | 3.81 | Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015) |
| "Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown." | 3.79 | Influence of ivabradine on reverse remodelling during mechanical unloading. ( Dias, P; Gandhi, A; Ibrahim, M; Navaratnarajah, M; Sarathchandra, P; Shah, A; Siedlecka, U; Terracciano, CM; van Doorn, C; Yacoub, MH, 2013) |
| "Chronic treatment with ketamine caused significant ventricular myocardial apoptosis, fibrosis and sympathetic sprouting, which altered the electrophysiological properties of the heart and increased its susceptibility to malignant arrhythmia that may lead to sudden cardiac death." | 3.78 | Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. ( Dong, DL; Geng, JQ; Gong, YT; Gong, ZH; Han, CL; Li, WM; Li, Y; Liu, GZ; Liu, L; Pan, ZW; Sheng, L; Shi, J; Sun, DH; Tan, XY; Yang, BF, 2012) |
| " Here, we demonstrate that metoprolol, a β(1)-adrenergic receptor-selective blocker, could induce cardiac fibrosis through a G protein-independent and β-arrestin2-dependent pathway." | 3.78 | Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. ( Chikura, S; Ide, T; Koyanagi, S; Kurose, H; Mangmool, S; Mizuno, N; Mochinaga, K; Nakaya, M; Nishida, M; Ohdo, S; Sato, Y; Watari, K, 2012) |
| " More importantly, ruboxistaurin prevented death in wild-type mice throughout 10 weeks of pressure-overload stimulation, reduced ventricular dilation, enhanced ventricular performance, reduced fibrosis, and reduced pulmonary edema comparable to or better than metoprolol treatment." | 3.75 | Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. ( Chen, X; Houser, SR; Kranias, EG; Leitges, M; Liu, Q; Lorenz, JN; Macdonnell, SM; Molkentin, JD, 2009) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 3.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "One day after induction of anti-thy1 glomerulonephritis, rats were given increasing doses of the beta-blockers metoprolol or nebivolol (0." | 3.72 | Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis. ( Gaedeke, J; Ketteler, M; Liefeldt, L; Neumayer, HH; Peters, H; Rückert, M; Sharma, AM, 2003) |
| "Pretreatment with propranolol and metoprolol improved survival to 90% and 100% respectively, compared with 60% in the ISO group, but did not reduce the incidence and extent of akinesis or the structural damage." | 1.40 | Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy. ( Dai, W; Kloner, RA; Sachdeva, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, F | 1 |
| Wang, Q | 1 |
| Wang, Z | 1 |
| Zhang, X | 1 |
| Zhang, B | 1 |
| Wang, H | 1 |
| Zhang, K | 1 |
| Tang, YD | 1 |
| Zhang, Y | 2 |
| Ojamaa, K | 1 |
| Li, Y | 4 |
| Saini, AS | 1 |
| Carrillo-Sepulveda, MA | 1 |
| Rajagopalan, V | 1 |
| Gerdes, AM | 1 |
| Dai, H | 1 |
| Yuan, Y | 1 |
| Yin, S | 1 |
| Han, Y | 1 |
| Sun, L | 1 |
| Li, T | 1 |
| Xu, J | 1 |
| Sheng, L | 2 |
| Gong, Y | 1 |
| Qi, C | 1 |
| Shao, Y | 1 |
| Liu, X | 1 |
| Wang, D | 3 |
| Li, X | 1 |
| Sachdeva, J | 1 |
| Dai, W | 1 |
| Kloner, RA | 1 |
| Li, W | 1 |
| Yan, S | 1 |
| Zhao, J | 1 |
| Ding, X | 1 |
| Zhang, S | 1 |
| Liu, L | 2 |
| Peng, W | 1 |
| Li, H | 1 |
| Liu, Z | 1 |
| Nazeri, A | 1 |
| Elayda, MA | 1 |
| Segura, AM | 1 |
| Stainback, RF | 1 |
| Nathan, J | 1 |
| Lee, VV | 1 |
| Bove, C | 1 |
| Sampaio, L | 1 |
| Grace, B | 1 |
| Massumi, A | 1 |
| Razavi, M | 1 |
| Oosterhuis, NR | 1 |
| Bongartz, LG | 1 |
| Verhaar, MC | 1 |
| Cheng, C | 1 |
| Xu, YJ | 1 |
| van Koppen, A | 1 |
| Cramer, MJ | 1 |
| Goldschmeding, R | 1 |
| Gaillard, CA | 1 |
| Doevendans, PA | 1 |
| Braam, B | 1 |
| Joles, JA | 1 |
| Sun, T | 1 |
| Shen, LH | 1 |
| Chen, H | 1 |
| Li, HW | 1 |
| Guo, CY | 1 |
| Li, ZZ | 1 |
| Tang, CS | 1 |
| Liu, Q | 1 |
| Chen, X | 1 |
| Macdonnell, SM | 1 |
| Kranias, EG | 1 |
| Lorenz, JN | 1 |
| Leitges, M | 1 |
| Houser, SR | 1 |
| Molkentin, JD | 1 |
| Sharma, V | 1 |
| Sharma, A | 1 |
| Saran, V | 1 |
| Bernatchez, PN | 1 |
| Allard, MF | 1 |
| McNeill, JH | 1 |
| Shi, J | 1 |
| Yang, BF | 1 |
| Han, CL | 1 |
| Li, WM | 1 |
| Dong, DL | 1 |
| Pan, ZW | 1 |
| Liu, GZ | 1 |
| Geng, JQ | 1 |
| Tan, XY | 1 |
| Sun, DH | 1 |
| Gong, ZH | 1 |
| Gong, YT | 1 |
| Nakaya, M | 1 |
| Chikura, S | 1 |
| Watari, K | 1 |
| Mizuno, N | 1 |
| Mochinaga, K | 1 |
| Mangmool, S | 1 |
| Koyanagi, S | 1 |
| Ohdo, S | 1 |
| Sato, Y | 1 |
| Ide, T | 1 |
| Nishida, M | 1 |
| Kurose, H | 1 |
| Navaratnarajah, M | 1 |
| Ibrahim, M | 1 |
| Siedlecka, U | 1 |
| van Doorn, C | 1 |
| Shah, A | 1 |
| Gandhi, A | 1 |
| Dias, P | 1 |
| Sarathchandra, P | 1 |
| Yacoub, MH | 1 |
| Terracciano, CM | 1 |
| Morita, H | 1 |
| Suzuki, G | 1 |
| Mishima, T | 1 |
| Chaudhry, PA | 1 |
| Anagnostopoulos, PV | 1 |
| Tanhehco, EJ | 1 |
| Sharov, VG | 1 |
| Goldstein, S | 1 |
| Sabbah, HN | 1 |
| Peters, H | 1 |
| Rückert, M | 1 |
| Gaedeke, J | 1 |
| Liefeldt, L | 1 |
| Ketteler, M | 1 |
| Sharma, AM | 1 |
| Neumayer, HH | 1 |
| Kobayashi, M | 1 |
| Machida, N | 1 |
| Mitsuishi, M | 1 |
| Yamane, Y | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Plante, E | 1 |
| Lachance, D | 1 |
| Champetier, S | 1 |
| Drolet, MC | 1 |
| Roussel, E | 1 |
| Arsenault, M | 1 |
| Couet, J | 1 |
1 trial available for metoprolol and Cirrhosis
| Article | Year |
|---|---|
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
18 other studies available for metoprolol and Cirrhosis
| Article | Year |
|---|---|
Metoprolol Mitigates Ischemic Heart Remodeling and Fibrosis by Increasing the Expression of AKAP5 in Ischemic Heart.
Topics: A Kinase Anchor Proteins; Animals; Fibrosis; Heart; Heart Failure; Metoprolol; Quality of Life; Rats | 2022 |
Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Echocardiography; Ele | 2018 |
Metoprolol Inhibits Profibrotic Remodeling of Epicardial Adipose Tissue in a Canine Model of Chronic Obstructive Sleep Apnea.
Topics: Adipokines; Adipose Tissue; Animals; Cardiomyopathies; Chronic Disease; Disease Models, Animal; Dogs | 2019 |
The cardioprotective effects of icariin on the isoprenaline-induced takotsubo-like rat model: Involvement of reactive oxygen species and the TLR4/NF-κB signaling pathway.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Echocardiography; Fibrosis; Flavonoids; Humans; | 2019 |
Functional and histological assessment of an experimental model of Takotsubo's cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Echo | 2014 |
Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea.
Topics: Actins; Animals; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-Associated De | 2015 |
Comparative Efficacy of Nebivolol and Metoprolol to Prevent Tachycardia-Induced Cardiomyopathy in a Porcine Model.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Cardiac Pacing, Artificial; Cardiomyopathies; Disea | 2016 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Fibr | 2008 |
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Signaling; Cardiomegaly; Disease Models, Animal; Fibro | 2009 |
β-receptor antagonist treatment prevents activation of cell death signaling in the diabetic heart independent of its metabolic actions.
Topics: Adrenergic beta-Antagonists; Animals; bcl-Associated Death Protein; Caspase 3; Caveolins; Cell Death | 2011 |
Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol.
Topics: Analgesics; Animals; Apoptosis; Apoptosis Inducing Factor; Fibrosis; Heart Ventricles; Illicit Drugs | 2012 |
Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Arrestins; beta-Arrestins; Fibrosis; G-Protein-Coup | 2012 |
Influence of ivabradine on reverse remodelling during mechanical unloading.
Topics: Animals; Atrophy; Benzazepines; Calcium; Calcium Channels, L-Type; Excitation Contraction Coupling; | 2013 |
Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Chronic Disease; Dogs; Female; Fibrosis; Heart Diseases; Heart | 2002 |
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzopyrans; Biomark | 2003 |
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp | 2004 |
Benefits of long-term beta-blockade in experimental chronic aortic regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 2008 |